Skip to main content

Advertisement

Table 4 Active clinical trials combining radiation, miscellaneous

From: Current clinical trials testing the combination of immunotherapy with radiotherapy

NCT Number Phase Title Conditions Interventions RT Details Enrollment Sponsor/Collaborators
Interleukin 2
NCT02086721 Phase 1 Phase I Clinical Study Combining L19-IL2 With SABR in Patients With Oligometastatic Solid Tumor Solid Tumour L19-IL-2 (recombinant protein with IL-2) SBRT, 7.5-30 Gy in 1-8 fx 18 Maastricht Radiation Oncology
NCT01416831 Phase 2 Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma. Metastatic Melanoma IL-2 SBRT, 20 Gy × 1-2 fx 44 Providence Health & Services|Prometheus
NCT01896271 Phase 2 High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer Metastatic RCC, Melanoma IL-2 SBRT, 8-20 Gy in 1-3 fx 26 University of Texas Southwestern Medical Center|Prometheus
NCT01884961 Phase 2 Radiotherapy as an Immunological Booster in Patients With Metastatic Melanoma or Renal Cell Carcinoma Treated With High-dose Interleukin-2 Metastatic RCC, Melanoma IL-2 SBRT, 6-12 Gy × 3 fx 19 Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
NCT02306954 Phase 2 Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer Renal Cell Carcinoma IL-2 SBRT, 20 Gy × 2 fx 84 Providence Health & Services|Prometheus Laboratories
NCT02735850 Phase 2 Combination of SABR and L19-IL2 in Patients With Stage IV Lung Cancer (ImmunoSABR) Stage IV NSCLC, Limited Metastatic Disease L19-IL-2 SBRT 141 Maastricht Radiation Oncology
Other Cytokines
NCT01973322 Phase 2 Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized “Proof-of-principle” Phase II Study (ABSIDE) Metastatic Melanoma IFN-alfa IMRT, 8-12 Gy in 3 fx 24 Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
OX40 agonists
NCT01862900 Phase 1|Phase 2 Phase I/II Study of Stereotactic Body Radiation Therapy to Metastatic Lesions in the Liver or Lung in Combination With Monoclonal Antibody to OX40 (MEDI6469) in Patients With Progressive Metastatic Breast Cancer After Systemic Therapy Metastatic Breast Cancer OX40 antibody (MEDI6469) SBRT, 10-25 Gy in 1-2 fractions 40 Providence Health & Services
TLR agonists
NCT02180698 Phase 1 TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery Metastatic Sarcoma TLR-4 agonist (GLA-SE) RT, 5-6 fx over 2 wks 18 Fred Hutchinson Cancer Research Center
NCT02061449 Phase 1 Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma Cutaneous T-cell Lymphoma TLR3 agonist Poly-ICLC RT, 3 fx 24 New York University School of Medicine|Ludwig Institute for Cancer Research
NCT02254772 Phase 1|Phase 2 TLR9 Agonist SD-101, Ipilimumab, and Radiation Therapy in Treating Patients With Low-Grade Recurrent B-cell Lymphoma Recurrent Lymphoma TLR-9 agonist (SD-101), Ipilimumab local RT 27 Ronald Levy|National Cancer Institute (NCI)|Stanford University
NCT01421017 Phase 1|Phase 2 Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases Metastatic Breast Cancer TLR-7 agonist Imiquimod, Cyclophosphamide RT, 6 Gy × 5 fx 55 New York University School of Medicine|National Cancer Institute (NCI)
NCT01976585 Phase 1|Phase 2 In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy Lymphoma CDX-301, Poly-ICLC (TLR agonist) Low dose RT 30 Joshua Brody|Icahn School of Medicine at Mount Sinai
Cancer Vaccines
NCT01436968 Phase 3 Phase 3 Study of ProstAtak™ Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer Prostate cancer AdV-tk vs placebo, valacyclovir +/- ADT EBRT, 8 wks 711 Advantagene
NCT02446093 Phase 1|Phase 2 Neoadjuvant GMCI Plus mFOLFIRINOX and Chemoradiation for Non-Metastatic Pancreatic Adenocarcinoma (PaTK02) Pancreatic cancer AdV-tk, mFOLFIRINOX, gemcitabine EBRT 44 Ohio State University
NCT01833208   Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T Metastatic Prostate Cancer Sipuleucel-T High-dose 1 fx to bony metastasis 15 Roswell Park Cancer Institute|National Cancer Institute (NCI)|Dendreon
NCT01818986 Phase 2 Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC) Metastatic Prostate Cancer Sipuleucel-T SBRT, metastatic site 41 University of Texas Southwestern Medical Center
NCT02232230 Phase 2 A Multicenter Trial Enrolling Men With Advanced Prostate Cancer Who Are to Receive Combination Radiation and Sipuleucel-T Metastatic Prostate Cancer Sipuleucel-T RT, metastatic site 100 21st Century Oncology|Dendreon